United Therapeutics Corporation (NASDAQ:UTHR) Stock Has Average Price Target of $627.31

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given an average recommendation of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $627.31.

Several brokerages recently weighed in on UTHR. Royal Bank Of Canada upped their price objective on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Morgan Stanley lifted their target price on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Finally, Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th.

Insider Transactions at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $167,432,054.58. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 374,228 shares of company stock worth $193,237,401. 8.60% of the stock is owned by corporate insiders.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Toth Financial Advisory Corp raised its stake in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $30,000. Caitlin John LLC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $37,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new stake in United Therapeutics in the 2nd quarter valued at $81,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $543.40 on Friday. The business has a fifty day moving average price of $513.17 and a two-hundred day moving average price of $540.27. United Therapeutics has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The stock has a market capitalization of $23.31 billion, a PE ratio of 19.44, a PEG ratio of 3.94 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the business posted $6.41 EPS. The company’s revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics will post 26.40 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.